Standout Papers

Daratumumab, Bortezomib, ... 2015 2026 2018 2022 2016 2015 2015 2015 2015 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
    2016 1.0k citations Antonio Palumbo, Asher Chanan‐Khan et al. New England Journal of Medicine profile →
  2. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
    2015 592 citations Alessandro M. Vannucchi, Jean‐Jacques Kiladjian et al. New England Journal of Medicine profile →
  3. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 474 citations Craig H. Moskowitz, Auayporn Nademanee et al. The Lancet profile →
  4. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
    2015 380 citations Owen A. O’Connor, Steven M. Horwitz et al. Journal of Clinical Oncology profile →
  5. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
    2015 337 citations Animesh Pardanani, Claire Harrison et al. JAMA Oncology profile →

Immediate Impact

7 by Nobel laureates 16 from Science/Nature 57 hit
Sub-graph 1 of 21

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 HitScience
Natural killer cell therapies
2024 HitNature
4 intermediate papers

Works of Tamás Masszi being referenced

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
2015 Hit
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
2015 Hit

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Tamás Masszi 3.8k 2.3k 2.3k 2.3k 1.1k 187 6.1k
Sigurður Y. Kristinsson 3.8k 1.0× 1.6k 0.7× 2.6k 1.1× 2.2k 1.0× 826 0.7× 142 6.0k
Haifa Kathrin Al‐Ali 3.2k 0.8× 820 0.4× 3.2k 1.4× 1.7k 0.7× 750 0.7× 166 4.9k
Uday Popat 4.0k 1.0× 1.9k 0.8× 1.5k 0.7× 1.3k 0.6× 969 0.9× 396 6.5k
Javier Pinilla‐Ibarz 2.6k 0.7× 1.8k 0.8× 2.3k 1.0× 1.9k 0.8× 767 0.7× 234 5.8k
Miloslav Beran 3.3k 0.9× 1.1k 0.5× 2.6k 1.1× 2.0k 0.9× 1.1k 1.0× 106 5.6k
Sa A. Wang 3.1k 0.8× 1.2k 0.5× 1.8k 0.8× 934 0.4× 1.2k 1.1× 278 5.3k
Taghi Manshouri 3.1k 0.8× 1.3k 0.5× 3.1k 1.4× 3.0k 1.3× 739 0.7× 142 6.2k
Dieter K. Hossfeld 1.9k 0.5× 1.8k 0.8× 1.4k 0.6× 2.6k 1.1× 1.2k 1.1× 165 6.1k
Ashraf Badros 4.4k 1.1× 3.5k 1.5× 1.1k 0.5× 3.3k 1.5× 677 0.6× 173 7.1k
Ulrike Bacher 4.2k 1.1× 1.1k 0.5× 2.1k 0.9× 1.8k 0.8× 624 0.6× 280 5.7k

All Works

Loading papers...

Rankless by CCL
2026